
Please try another search
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization. In addition, the company is involved in the provision of consultation on pharmaceutical technology; and manufacture and sale of health food. The company was founded in 2001 and is based in Taipei City, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Shih-Jen Hsiao | - | 2013 | Supervisor |
Chiung-Feng Ko | - | 2012 | Supervisor |
Ta-Shao Shih | - | 2015 | Supervisor |
Hong-Jen Chang | 67 | 2010 | Director |
Weng-Foung Huang | - | - | Independent Director |
Kuo-Lung Huang | - | 2019 | Chairman of the Board |
Ye-Hong Zhang | 62 | 2019 | Independent Director |
I-Jen Huang | - | 2025 | Director |
Yi-Chun Huang | - | 2025 | Independent Director |
Hsun Yuan Tsou | - | 2025 | Director |
Mei-Li Su | - | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review